The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | 45-month CheckMate 648 results show nivolumab combos’ sustained benefits in ESCC
Ian Chau, MD, Royal Marsden Hospital, London, UK, discusses the 45-month follow-up results of the Phase III CheckMate 648 study (NCT03143153) evaluating nivolumab with chemotherapy or ipilimumab in patients with advanced esophageal squamous cell carcinoma (ESCC) in the first-line setting. The study demonstrated that both combinations provided sustained overall survival benefits and durable responses compared to chemotherapy alone, with an improved duration of response. Safety profiles remained consistent with previous reports, with no new adverse events identified. These sustained safety outcomes contribute positively to the overall benefit-risk assessment of these combination therapies. Clinicians should consider the management of adverse events associated with these regimens, ensuring vigilant monitoring and proactive management to optimize patient outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role – Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding – Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses – BMS; SERVIER
